China’s National Medical Products Administration (NMPA) approved Suzhou Alphamab’s HER2 bispecific antibody anbenitamab (KN-026) through priority review for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma. The label covers patients who have received at least one trastuzumab-containing regimen. The approval adds another targeted option to the post-trastuzumab landscape, where clinical teams are actively seeking therapies that can deepen response while maintaining tolerability. For Alphamab, priority review signals fast-track regulatory alignment with the evidence package. Commercially, the move increases competitive intensity among HER2-directed agents in China, with downstream attention likely turning to how anbenitamab is sequenced with chemotherapy and other HER2 strategies in real-world treatment patterns.